Drug evaluation: E-5564.
Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological effects of endotoxin-mediated responses caused by bacterial infection, including septic shock.
Ondiveeran
Hari Kumar
HK
McMaster University, Department of Medicine, Regional Critical Care Programme and the Intestinal Disease Research Programme, Faculty of Health Sciences, HSC 4N52, 1200 Main St West, Hamilton, ON, L8N 3Z5, Canada.
Fox-Robichaud
Alison
A
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D019446:Endotoxemia / Q000188:drug therapy*; D004731:Endotoxins / Q000037:antagonists & inhibitors*; D006801:Humans; D008050:Lipid A / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D016032:Randomized Controlled Trials as Topic; D018805:Sepsis / Q000188:drug therapy; D013329:Structure-Activity Relationship
C404742:E5564; D004731:Endotoxins; D008050:Lipid A